A Food and Drug Administration advisory panel's recommendation to pull an early birth drug from the market is only the latest controversy surrounding a popular program aimed at getting promising new treatments to patients faster.
Why it matters: Critics — including the FDA itself — say the program lacks the appropriate guardrails, putting expensive, unproven treatments in consumers' hands while drugmakers often delay proving the drugs' effectiveness.
